Novo Nordisk A/S (NYSE:NVO) Upgraded by Kepler Capital Markets to “Buy” Rating

Novo Nordisk A/S (NYSE:NVO) was upgraded by equities researchers at Kepler Capital Markets from a “hold” rating to a “buy” rating in a report released on Thursday,Briefing.com Automated Import reports.

Several other brokerages have also issued reports on NVO. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Down 4.3 %

NVO opened at $74.75 on Thursday. The firm has a market capitalization of $335.42 billion, a P/E ratio of 22.72, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a one year low of $73.80 and a one year high of $148.15. The company has a fifty day moving average price of $84.39 and a 200-day moving average price of $103.83. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently bought and sold shares of NVO. Natixis Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares during the last quarter. Norman Fields Gottscho Capital Management LLC boosted its position in Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after buying an additional 19,870 shares during the period. Bryn Mawr Capital Management LLC grew its holdings in Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock worth $3,346,000 after acquiring an additional 30,420 shares during the last quarter. Versant Capital Management Inc bought a new stake in Novo Nordisk A/S in the 4th quarter worth $86,000. Finally, Talbot Financial LLC purchased a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $4,066,000. 11.54% of the stock is currently owned by institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.